Argenica Therapeutics Limited (ASX:AGN) is developing novel neuroprotective therapeutics to reduce brain damage after stroke and other devastating brain injuries

Every 19 minutes someone in Australia will suffer a new stroke. Globally, there were 13 million people who experienced a stroke for the first time in their lives in 2019. When a stroke strikes, it can cause lasting brain damage, long term disability, and even death. Protecting the brain is crucial for improving patient outcomes and recovery.

Discover More

About Argenica Therapeutics

A clinical stage drug development company developing novel therapeutics for stroke and other types of brain injuries

Based on research from The University of Western Australia and the Perron Institute for Neurological and Translational Science, Argenica’s lead candidate ARG-007 aims to protect brain cells and reduce cell death following a stroke, and other types of brain injury, in order to minimise the impact of these conditions and improve patient recovery.

Ultimately, in acute brain injury, our aim is for ARG-007 to be administered by first responders to protect brain tissue against damage during a stroke and other types of acute injury such as severe traumatic brain injury, with further potential to enhance recovery once the injury has taken place. Our investor centre will provide you all the information you need to stay across the details for investing in Argenica Therapeutics (ASX: AGN) as we bring this exciting product to market.

About UsOur PeopleInvestor Centre

Therapeutic Drug Development

Developing a "best in class" novel neuroprotective therapeutic

Our lead neuroprotective peptide candidate, ARG-007, has been successfully demonstrated in pre-clinical animal models of stroke, traumatic brain injury, and hypoxic ischaemic encephalopathy, showing a reduction in brain cell death. ARG-007 has also proven safe and well tolerated in a Phase 1 clinical trial conducted in healthy human volunteers. ARG-007 will shortly be tested for safety and efficacy in acute ischaemic stroke patients presenting to emergency departments across Australia.

The ScienceDevelopment

Subscribe to our mailing list to stay up to date with Argenica Therapeutics